Abstract
The detection of β-thalassemia carriers is based on the correct estimation of HbA2 values.The diagnosis of β-thalassemia carriers may be more complicated in presence of δ-thalassemia because the interaction between δ and β-globin gene defects modifies the HbA2 values. For this reason, we studied the spectrum of δ-globin gene mutations present in the Sicilian population, characterized by its very high heterogeneity in β-thalassemia genotype and phenotype. The samples were selected by screening and routine prenatal diagnoses counseling for thalassemia. Among 7153 samples studied for β-thalassemia, 205 samples were selected for HbA2 levels ranging from 0.5% to 2.0% and normal haematology parameters, suspected of being δ-thal carriers in the absence of α and β-thalassemia or hemoglobin variants, and for HbA2 levels from 2.1% to 4.6% in subjects suspected of compound heterozygotes for δ and β-thalassemia and between 1.4% and 2.0% for δ and α-thalassemia. We have considered the value of 2% as the treshold between normal and d-carrier subjects. One-hundred-eighty-three samples showed to be positive for δ-globin gene mutations.Twelve mutations were detected and among these five were new δ-globin gene defects (HbA2-Catania, HbA2-Corleone, HbA2-Ventimiglia; HbA2-Montechiaro and HbA2-Bagheria) determining δ-globin gene variants and seven were already described mutations. Among these six of them were point mutations (HbA2-Mitsero, HbA2-NYU,HbA2-Yialousa, HbA2-Coburg, HbA2-Fitzroy) and one a 7.2 Kb deletion mutation known as the δ-Corfù type, HBD g.5946_1262del. As it was previously shown in Sicily for β-thalassemia, only three mutations account for 91% (HbA2-Yialousa, HbA2-NYU, IVS II-3′ A→G) of the overall δ-globin gene defects. HbA2-Yialousa (g.82G→T) is the most common mutation found in Sicilian population (81%) while the other eleven mutations are less frequent between 0.5 to 5.5%. These findings suggest that in Sicily δ-thalassemia is very common (2.5%) and as it was described, previously, for the β-thalassemia mutations,this also is very heterogeneous (twelve mutations). This information is noteworthy considering the implication that the interaction between β and δ-thalassemia could determine in terms of HbA2 decrease in subjects heterozygotes for β-thalassemia.
βA/βA | αα/αα | Gγ-158/Gγ | 1.1 | 1 | |
βA/βA | αα/αα | 1.7±0.2 | 113 | ||
βA/βA | αα/αα | 2.1±0.1 | 4 | ||
βA/βA | αα/αα | 0.7±0.1 | 3 | ||
βA/β(IVS1,110) | αα/αα | 3.35±0.15 | 2 | ||
βA/β(cd39) | αα/αα | 3.5 | 1 | ||
Hb A2-Yialousa | βA/β(IVS1,1) | αα/αα | 3.5 | 1 | |
βA/β(−87G) | αα/αα | 4.6 | 1 | ||
βA/β(−101) | αα/αα | 2.8 | 1 | ||
βA/β(IVS1,6) | αα/αα | 3.0±0.2 | 4 | ||
βA/βS | αα/αα | 2.7±0.1 | 5 | ||
βA/βA | α−3.7α/αα | 1.8±0.2 | 5 | ||
βA/βA | α−20.5α/αα | 1.4±0.1 | 2 | ||
βA/βA | α−Medα/αα | 1.6±0.1 | 2 | ||
βA/βA | αNcoIα/αα | 1.7±0.2 | 2 | ||
βA/βA | αHphIα/αα | 1.7±0.2 | 2 | ||
Hb A2-NYU | βA/βA | αα/αα | 1.5±0.2 | 9 | |
βA/β(Valletta) | α−3.7α/αα | 1.6 | 1 | ||
Hb A2-Mitsero | βA/βA | αα/αα | 1.9±0.2 | 3 | |
βA/βA | α−3.7α/αα | 1.6 | 1 | ||
Hb A2-Coburg | βA/βA | αα/αα | 1 | 1 | |
Hb A2-Fitzroy | βA/βA | αα/αα | 1.4±0.2 | 3 | |
Hb A2-Catania | βA/βA | αα/αα | 1.2 | 1 | |
Hb A2-Corleone | βA/βA | αα/αα | 1.6 | 1 | |
Hb A2-Ventimiglia | βA/βA | αα/αα | 2 | 1 | |
Hb A2-Montechiaro | βA/βA | αα/αα | 1.3 | 1 | |
Hb A2-Bagheria | βA/βA | αα/αα | 1.7 | 1 | |
7.2 Kb deletion | βA/βA | αα/αα | 1.4±0.1 | 3 | |
βA/βA | αα/αα | 1.5±0.2 | 4 | ||
IVS II-3′ | βA/β(IVS1,110) | αα/αα | 3.3±0.2 | 3 | |
βA/β | αα/ααα | 2.5 | 1 | ||
GENOTYPE δ | GENOTYPEβ | GENOTYPEα | GENOTYPEγ | HbA2% | N° OF δ CARRIERS |
βA/βA | αα/αα | Gγ-158/Gγ | 1.1 | 1 | |
βA/βA | αα/αα | 1.7±0.2 | 113 | ||
βA/βA | αα/αα | 2.1±0.1 | 4 | ||
βA/βA | αα/αα | 0.7±0.1 | 3 | ||
βA/β(IVS1,110) | αα/αα | 3.35±0.15 | 2 | ||
βA/β(cd39) | αα/αα | 3.5 | 1 | ||
Hb A2-Yialousa | βA/β(IVS1,1) | αα/αα | 3.5 | 1 | |
βA/β(−87G) | αα/αα | 4.6 | 1 | ||
βA/β(−101) | αα/αα | 2.8 | 1 | ||
βA/β(IVS1,6) | αα/αα | 3.0±0.2 | 4 | ||
βA/βS | αα/αα | 2.7±0.1 | 5 | ||
βA/βA | α−3.7α/αα | 1.8±0.2 | 5 | ||
βA/βA | α−20.5α/αα | 1.4±0.1 | 2 | ||
βA/βA | α−Medα/αα | 1.6±0.1 | 2 | ||
βA/βA | αNcoIα/αα | 1.7±0.2 | 2 | ||
βA/βA | αHphIα/αα | 1.7±0.2 | 2 | ||
Hb A2-NYU | βA/βA | αα/αα | 1.5±0.2 | 9 | |
βA/β(Valletta) | α−3.7α/αα | 1.6 | 1 | ||
Hb A2-Mitsero | βA/βA | αα/αα | 1.9±0.2 | 3 | |
βA/βA | α−3.7α/αα | 1.6 | 1 | ||
Hb A2-Coburg | βA/βA | αα/αα | 1 | 1 | |
Hb A2-Fitzroy | βA/βA | αα/αα | 1.4±0.2 | 3 | |
Hb A2-Catania | βA/βA | αα/αα | 1.2 | 1 | |
Hb A2-Corleone | βA/βA | αα/αα | 1.6 | 1 | |
Hb A2-Ventimiglia | βA/βA | αα/αα | 2 | 1 | |
Hb A2-Montechiaro | βA/βA | αα/αα | 1.3 | 1 | |
Hb A2-Bagheria | βA/βA | αα/αα | 1.7 | 1 | |
7.2 Kb deletion | βA/βA | αα/αα | 1.4±0.1 | 3 | |
βA/βA | αα/αα | 1.5±0.2 | 4 | ||
IVS II-3′ | βA/β(IVS1,110) | αα/αα | 3.3±0.2 | 3 | |
βA/β | αα/ααα | 2.5 | 1 | ||
GENOTYPE δ | GENOTYPEβ | GENOTYPEα | GENOTYPEγ | HbA2% | N° OF δ CARRIERS |
Author notes
Corresponding author